ScreenerHero

OABIOmniAb Inc. Common Stock

NAS · US · Healthcare · Biotechnology · omniab.com
4.330USD+3.34%Mkt Cap: 629.54M $P/E: —

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap629.54M $
Enterprise Value592.10M $
Revenue (TTM)38.46M $
Gross Profit18.36M $
Net Income (TTM)-64.78M $
Revenue/Share0.3080 USD
Last Price4.330 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees89
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.58
PEG—
EV/EBITDA-27.42
EV/Revenue15.40
P/S16.26
P/B2.40
EPS (TTM)-0.37
EPS (Forward)-0.29
52W Range
1.30094% of range4.535
52W High4.535 USD
52W Low1.300 USD
Profitability
Gross Margin98.38%
Oper. Margin-49.47%
EBITDA Margin-56.16%
Profit Margin-347.04%
ROE-24.26%
ROA-21.53%
Growth
Revenue Growth244.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.45M $
CapEx (TTM)565.00K $
FCF Margin-0.74%
FCF Yield-0.05%
Net Debt-33.08M $
Net Debt/EBITDA1.53
Balance Sheet
Debt/Equity0.08
Current Ratio4.80
Quick Ratio4.53
Book Value/Sh1.790 USD
Cash/Share0.3580 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.667 USD
Upside (mean)+77.1%
Target Range4.000 USD – 11.00 USD
$4.000+77.1% to mean$11.00
# Analysts6
Ownership
Shares Out.145.39M
Float118.24M
Insiders15.28%
Institutions52.78%
Short Interest
Short Ratio13.1d
Short % Float4.53%
Short % Out.4.12%
Shares Short6.00M
Short (prev mo.)4.75M
Technical
SMA 502.483 (+74.4%)
SMA 2001.992 (+117.3%)
Beta1.22
S&P 52W Chg18.16%
Avg Vol (30d)1.29M
Avg Vol (10d)3.47M
Technical Indicators
RSI (14)88.9
MACD0.4893
MACD Signal0.2937
MACD Hist.+0.1956
BB Upper4.440 USD
BB Middle2.732 USD
BB Lower1.024 USD
BB Width125.04%
ATR (14)0.2715 USD
Vol Ratio (20d)1.12x